Journal article
Haemolytic uraemic syndrome
The Lancet (British edition), Vol.400(10364), pp.1722-1740
10/19/2022
DOI: 10.1016/S0140-6736(22)01202-8
Abstract
Haemolytic uraemic syndrome (HUS) is a heterogeneous group of diseases that result in a common pathology, thrombotic microangiopathy, which is classically characterised by the triad of non-immune microangiopathic haemolytic anaemia, thrombocytopenia, and acute kidney injury. In this Seminar, different causes of HUS are discussed, the most common being Shiga toxin-producing Escherichia coli HUS. Identifying the underlying thrombotic microangiopathy trigger can be challenging but is imperative if patients are to receive personalised disease-specific treatment. The quintessential example is complement-mediated HUS, which once carried an extremely high mortality but is now treated with anti-complement therapies with excellent long-term outcomes. Unfortunately, the high cost of anti-complement therapies all but precludes their use in low-income countries. For many other forms of HUS, targeted therapies are yet to be identified.
Details
- Title: Subtitle
- Haemolytic uraemic syndrome
- Creators
- Mini Michael - Texas Children's HospitalArvind Bagga - Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, IndiaSarah E Sartain - Pediatrics-Hematology/Oncology, Baylor College of Medicine, Houston, TX, USARichard J H Smith - University of Iowa
- Resource Type
- Journal article
- Publication Details
- The Lancet (British edition), Vol.400(10364), pp.1722-1740
- Publisher
- Elsevier Ltd
- DOI
- 10.1016/S0140-6736(22)01202-8
- ISSN
- 0140-6736
- eISSN
- 1474-547X
- Language
- English
- Date published
- 10/19/2022
- Academic Unit
- Internal Medicine; Anatomy and Cell Biology; Iowa Neuroscience Institute; Otolaryngology; Stead Family Department of Pediatrics; Molecular Physiology and Biophysics; Roy J. Carver Department of Biomedical Engineering
- Record Identifier
- 9984306859202771
Metrics
10 Record Views